Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells

Abstract

We recently reported that knockdown of delta-5-desaturase (a key enzyme that converts dihomo-γ-linolenic acid, DGLA, to the downstream ω-6 arachidonic acid) promotes formation of an anti-cancer byproduct 8-hydroxyoctanoic acid from cyclooxygenase (COX)-catalyzed DGLA peroxidation. 8-hydroxyoctanoic acid can exert its growth inhibitory effect on cancer cells (e.g. colon and pancreatic cancer) by serving as a histone deacetylase inhibitor. Since histone deacetylase inhibitors have been well-known to suppress cancer cell migration and invasion, we thus tested whether knockdown of delta-5-desaturase and DGLA treatment could also be used to inhibit cancer migration and invasion of colon cancer and pancreatic cancer cells. Wound healing assay, transwell assay and western blot were used to assess cell migration and invasion as well as the associated molecular mechanisms. Formation of threshold level of 8-hydroxyoctanoic acid was quantified from COX-catalyzed DGLA peroxidation in the cancer cells that overexpress COX-2 and their delta-5-desaturases were knocked down by shRNA transfection. Our results showed that knockdown of delta-5-desaturase along with DGLA supplement not only significantly inhibited cell migration, but also improved the efficacies of 5-flurouracil and gemcitabine, two frontline chemotherapy drugs currently used in the treatment of colon and pancreatic cancer, respectively. The molecular mechanism behind these observations is that 8-hydroxyoctanoic acid inhibits histone deacetylase, resulting in downregulation of cancer metastasis promotors, e.g., MMP-2 and MMP-9 as well as upregulation of cancer metastasis suppressor, e.g. E-cadherin. For the first time, we demonstrated that we could take the advantage of the common phenomenon of COX-2 overexpression in cancers to inhibit cancer cell migration and invasion. With the shifting paradigm of COX-2 cancer biology, our research outcome may provide us a novel cancer treatment strategy.

RETRACTED ARTICLE: Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activating the mROS-HtrA2/Omi pathways

“…Cells were washed twice with PBS, permeabilized in 0.1% Triton X-100 overnight at 4 °C. After the fixation procedure, the sections were cryoprotected in a PBS solution supplemented with 0.9 mol/l of sucrose overnight at 4 °C [ 34 ]. The primary antibodies used in the present study were as follows: caspase9 (1:1000, Cell Signaling Technology, #9504), Mff (1:1000, Cell Signaling Technology, #86668), Tom20 (1:1000, Abcam, #ab186735), HrtA2/Omi (1:1000; Abcam; #ab32092).…”

Mammalian STE20-Like Kinase 1 Deletion Alleviates Renal Ischaemia-Reperfusion Injury via Modulating Mitophagy and the AMPK-YAP Signalling Pathway

“…For example, FUNDC1, the mitochondrial outer membrane proteins, has been acknowledged as the guard of heart function in the setting of acute IR injury [66]. In addition, Bnip3, another mitochondrial receptor, exerts beneficial effects on high-fat-treated livers [67]. In the present study, we explored the role of OPA1 in renal I/R injury.…”

FADS1 promotes the progression of laryngeal squamous cell carcinoma through activating AKT/mTOR signaling

“…Fatty acid desaturase 1 (FADS1) is the key rate-limiting enzyme of the bioactive metabolites which convert dihomo-gamma-linolenic acid (DGLA) to AA 18 . Previous studies have shown that the expression of FADS1 was dysregulated in many cancers and that knockdown of FADS1 not only inhibited cancer growth and migration but also enhanced the cytotoxicity of chemotherapeutic agents [19][20][21][22] . However, the molecular mechanism of FADS1 in laryngeal cancer still remain to be elucidated.…”